by Biktarvy

Biktarvy Tablets

Bictegravir

Biktarvy Tablets is a trusted medication containing Bictegravir & Emtricitabine & Tenofovir, designed for personal use under the guidance of a healthcare professional. Available for prescription-based international supply with discreet worldwide delivery.

Quick Facts

Active ingredient: Bictegravir
Form: Tablet
Indication: HIV-1 infection
Manufacturer: Biktarvy

This medicine is available to order. Contact us for current pricing and availability.

Secure SSL

Discreet Packaging

Lab Tested

Rx Verified

Overview

What is Bictegravir?

Bictegravir is a next-generation HIV integrase inhibitor available only as part of the fixed-dose combination Biktarvy (bictegravir 50 mg / tenofovir alafenamide 25 mg / emtricitabine 200 mg). It has a high barrier to resistance and requires no pharmacokinetic boosting, making it a preferred first-line regimen.

Mechanism

How Does It Work?

Integrase strand transfer inhibition

Bictegravir chelates Mg2+ at the integrase active site and prevents viral DNA integration into host chromosomes.

High resistance barrier

Bictegravir's binding contacts tolerate fewer escape mutations compared to earlier INSTIs, giving it a higher genetic barrier to resistance.

Unboosted pharmacokinetics

Unlike some older INSTIs, bictegravir reaches therapeutic concentrations without ritonavir or cobicistat boosting, simplifying the regimen.

Dosage

How to Use

Timing

Once daily, at the same time each day

How to Take

Swallow one Biktarvy tablet whole. Can be taken with or without food.

Frequency

Once daily

With Food

Can be taken with or without food

Alcohol

Avoid excessive alcohol

Missed Dose

Take as soon as remembered the same day. Do not take two doses on the same day.

Safety

Side Effects & Precautions

Common Side Effects

Diarrhoea
Nausea
Headache
Fatigue
Dizziness

Serious Side Effects — seek help immediately

Immune reconstitution syndrome
Lactic acidosis
Severe hepatomegaly (from TAF/FTC components)
HBV flare on discontinuation in HBV co-infected patients

Who Should Not Take This

Concurrent use of rifampicin (reduces bictegravir levels)
Concurrent use of dofetilide
Severe hepatic impairment

Value

Generic vs Brand

Generic (OnlineMeds)

Biktarvy

Price per unit

—

$3000–$4000/month

Active ingredient

Identical

WHO-GMP certified

✓

Bioequivalent

✓

Reference

Storage

Storage & Handling

Temperature

Below 30°C

Light

Keep in original bottle

Humidity

Do not remove desiccant; protect from moisture

Children

Keep out of reach of children.

Why OnlineMeds

Why Buy From Us

Manufacturer Direct

Sourced directly from WHO-GMP certified manufacturers.

Quality Verified

Every batch tested for purity and bioequivalence.

Global Delivery

Discreet shipping to UK, US, AU, EU and beyond.

Licensed Pharmacy

Regulated and compliant with international pharmacy standards.

FAQ

Frequently Asked Questions

Is Biktarvy Tablets a complete HIV regimen on its own?

Yes. Biktarvy (bictegravir/TAF/emtricitabine) is a complete single-tablet HIV regimen. It contains three active antiretroviral agents covering two mechanisms (INSTI + two NRTIs), so no additional HIV drugs are needed.

Does Bictegravir work against drug-resistant HIV?

Bictegravir has a higher genetic barrier to resistance than earlier integrase inhibitors such as raltegravir, meaning more mutations are required before resistance develops. It may retain activity against some raltegravir-resistant strains, but this depends on the specific mutations present.

What happens if I miss a dose of Biktarvy Tablets?

Take the missed dose as soon as you remember on the same day. If you only remember the next day, skip the missed dose and take your regular dose as scheduled. Do not take two tablets on the same day.

Why should Biktarvy Tablets not be stopped suddenly if I have Hepatitis B?

Biktarvy contains tenofovir alafenamide and emtricitabine, both of which suppress Hepatitis B virus as well as HIV. Stopping suddenly can cause a severe flare of HBV infection that may cause serious liver damage. Never stop without medical supervision if you have HBV co-infection.

⚠ BLACK BOX WARNING

Severe acute exacerbation of Hepatitis B may occur in HBV co-infected patients upon discontinuation of Biktarvy. Hepatic function should be monitored closely for at least several months after stopping.

Drug Interactions

Drug / Substance	Effect	Action
Rifampicin	Significantly reduces bictegravir exposure	Contraindicated
Rifabutin	Reduces bictegravir exposure moderately	Avoid if possible; consult specialist
Antacids with Mg2+/Al3+	May reduce bictegravir absorption	Separate administration by at least 2 hours
St John's Wort	P-gp induction reduces bictegravir levels	Avoid concurrent use

Approved Indications

HIV-1 infection in adults and children ≥ 2 years weighing ≥ 14 kg FDA / EMA

References

Gilead Sciences. FDA Prescribing Information: Biktarvy (bictegravir/TAF/emtricitabine). ↗
DHHS. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents, 2023. ↗

Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting, stopping, or changing any medication. Used as prescribed by a licensed medical professional.

Biktarvy Tablets Order Now